Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation

Corneal Perforation Clinical Trial

Official title:

Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03500796
• Other study ID #: 56-2/2018
• Status: Completed
• Phase: N/A
• Start date: April 15, 2018
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2021
• Source: Minia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Use of amniotic membrane(AMT) and platelet rich plasma (PRP) clot for closure of central corneal perforation

Description:

Use of amniotic membrane and platelet rich plasma clot for closure of central corneal perforation either post infective or posttraumatic

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• central corneal perforation

Exclusion Criteria:

• active infection

• posterior segment pathology

• non seeing eye

Related Conditions & MeSH terms

• Corneal Perforation

Intervention

Procedure:
• Platelet rich plasma clot implantation
Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
• Wound closure with amniotic membrane
Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin

Locations

Country	Name	City	State
Egypt	Faculty of Medicine	Minya

Sponsors (1)

Lead Sponsor	Collaborator
Minia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Closure of the corneal wound	sealing of the edges corneal gap, with formation of scar tissue	3 months